Value through Innovation02 September 2014

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

31.01.2012

FDA approves Jentadueto™ (linagliptin/metformin hydrochloride) tablets for the treatment of adults with Type 2 Diabetes

- For Non-U.S. and Non-UK Media
26.01.2012

Boehringer Ingelheim launches ‘Lean-to-Clinic’ program for fast drug product supply

26.01.2012

Boehringer Ingelheim Moves into Phase III for its Head and Neck Cancer Trial Programme for Afatinib*

- FOR NON-US MEDIA ONLY
14.12.2011

Boehringer Ingelheim significantly expands its supply center for China

09.12.2011

Boehringer Ingelheim completes patient entry for Phase III trial
programme in Hepatitis C

- For media outside the U.S.
08.12.2011

Linagliptin demonstrates meaningful improvement in glycaemic control in initial combination therapy with metformin

- EX US, UK and UAE Medical Media Only. Under embargo until 08 Dec, 10 am CET
07.12.2011

Winners of the Making More Health Competition Bring Fresh Innovation to Solving Problems in Health

01.12.2011

Boehringer Ingelheim and AVEO Pharmaceuticals announce manufacturing agreement for ficlatuzumab

23.11.2011

Pradaxa® awarded Prix Galien for most innovative product in Canada

- For NON-US, Non-Canada and NON-UK Healthcare Media Only
17.11.2011

Boehringer Ingelheim race to the finish line in support of World Diabetes Day

- EX US and UK.
14.11.2011

New RE-LY® sub-analyses demonstrate safety and efficacy of Pradaxa® (dabigatran etexilate) in patients with heart failure & those undergoing surgery

- For NON-US, NON-Canada and NON-UK Healthcare Media Only
09.11.2011

Thirteen Finalists Chosen for Boehringer Ingelheim and Ashoka Changemakers "Making More Health" Competition

08.11.2011

BI 201335 demonstrates potential to shorten HCV treatment duration while achieving high sustained virological response rates in difficult to treat patients

- For media outside of the U.S.A only
07.11.2011

Hepatitis C: Interferon-free combination of BI 201335 plus BI 207127 and ribavirin shows up to 76% of patients achieve a virological response at week 12, and 59% achieve SVR12 with 16 weeks treatment

- For media outside of the U.S.A. only
04.11.2011

Boehringer Ingelheim gains approval of extended 4.5 hour time-window for Actilyse® in acute ischaemic stroke for majority of EU countries*

- For non-UK and non-US media
01.11.2011

NICE issues Final Appraisal Determination (FAD) with unrestricted recommendation for Pradaxa® (dabigatran etexilate) for patients with non-valvular atrial fibrillation

- For NON-US, UK & Canada Media Only
27.10.2011

Boehringer Ingelheim implements additional guidance supporting appropriate use of Pradaxa® (dabigatran etexilate) in Europe

- For European Health Media Only
06.10.2011

Boehringer Ingelheim and Gilead sign license agreement for novel HIV non-catalytic integrase inhibitors